LifeStance Health Group, Inc. (NASDAQ:LFST – Get Free Report) insider Ryan Pardo sold 2,216,585 shares of the stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $14.58, for a total value of $32,317,809.30. Following the completion of the transaction, the insider owned 334,935 shares in the company, valued at $4,883,352.30. The trade was a 86.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
Ryan Pardo also recently made the following trade(s):
- On Tuesday, November 10th, Ryan Pardo sold 587,920 shares of LifeStance Health Group stock. The shares were sold at an average price of $14.58, for a total value of $8,571,873.60.
LifeStance Health Group Trading Down 0.5%
Shares of LFST stock traded down $0.07 on Friday, reaching $14.08. 3,728,905 shares of the stock were exchanged, compared to its average volume of 6,598,220. The stock has a market cap of $5.35 billion, a PE ratio of 74.11 and a beta of 1.35. LifeStance Health Group, Inc. has a one year low of $6.01 and a one year high of $15.66. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.44 and a quick ratio of 1.44. The stock has a 50 day moving average price of $12.79 and a 200 day moving average price of $9.67.
LifeStance Health Group (NASDAQ:LFST – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.02. The business had revenue of $455.86 million for the quarter, compared to analyst estimates of $431.59 million. LifeStance Health Group had a return on equity of 4.82% and a net margin of 4.29%. The business’s revenue for the quarter was up 25.3% compared to the same quarter last year. Equities research analysts forecast that LifeStance Health Group, Inc. will post 0.18 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of research analysts have issued reports on the stock. Barclays upped their target price on shares of LifeStance Health Group from $13.00 to $15.00 and gave the company an “overweight” rating in a research report on Thursday, September 10th. Canaccord Genuity Group lifted their price target on shares of LifeStance Health Group from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Friday, November 6th. KeyCorp boosted their price target on shares of LifeStance Health Group from $15.00 to $17.00 and gave the stock an “overweight” rating in a research note on Friday, November 6th. JPMorgan Chase & Co. increased their price objective on shares of LifeStance Health Group from $13.00 to $15.00 and gave the company a “neutral” rating in a report on Thursday. Finally, BTIG Research raised their price objective on shares of LifeStance Health Group from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Thursday, November 5th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, LifeStance Health Group has a consensus rating of “Moderate Buy” and a consensus target price of $14.86.
View Our Latest Stock Report on LFST
Institutional Investors Weigh In On LifeStance Health Group
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Kovack Advisors Inc. acquired a new position in shares of LifeStance Health Group during the 3rd quarter worth about $177,000. Caxton Associates LLP raised its position in shares of LifeStance Health Group by 164.2% in the 3rd quarter. Caxton Associates LLP now owns 246,423 shares of the company’s stock valued at $2,964,000 after acquiring an additional 153,169 shares during the period. First Trust Advisors LP raised its position in shares of LifeStance Health Group by 62.6% in the 3rd quarter. First Trust Advisors LP now owns 1,438,471 shares of the company’s stock valued at $17,305,000 after acquiring an additional 553,736 shares during the period. Advisors Asset Management Inc. bought a new position in LifeStance Health Group during the 3rd quarter worth approximately $64,000. Finally, Landscape Capital Management L.L.C. bought a new position in LifeStance Health Group during the 3rd quarter worth approximately $335,000. Institutional investors own 85.50% of the company’s stock.
About LifeStance Health Group
LifeStance Health Group, Inc. is a U.S. provider of outpatient mental health services. The company offers care through in-person clinics and virtual appointments, connecting patients with behavioral health professionals. Its services include psychotherapy, psychiatric evaluations and medication management. LifeStance’s clinicians treat a range of mental health conditions, including anxiety, depression, attention-deficit/hyperactivity disorder and mood disorders. Founded in 2017, LifeStance has expanded its network across the United States.
Recommended Stories
- Five stocks we like better than LifeStance Health Group
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for LifeStance Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeStance Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
